Antibody against epstein-barr virus dna polymerase activity in sera of patients with nasopharyngeal carcinoma
β Scribed by Mei-Ying Liu; Wen-Hsiang Chou; Jen-Yang Chen; Dr. Czau-Siung Yang; Louise Nutter; Mow-Ming Hsu
- Publisher
- John Wiley and Sons
- Year
- 1989
- Tongue
- English
- Weight
- 451 KB
- Volume
- 28
- Category
- Article
- ISSN
- 0146-6615
No coin nor oath required. For personal study only.
β¦ Synopsis
A salt-dependent DNA polymerase activity was demonstrated in the culture of an EBV-producing, lymphoblastoid cell line (NPC-204 cells) treated with 5-iodo-2'-deoxyuridine (IUdR). There was a high frequency of levels of antibody to this enzyme in sera of patients with nasopharyngeal carcinoma (NPC). In contrast, sera from healthy subjects had little or no neutralizing activity. The high antibody level appeared as early as stage 1 of the disease in many NPC patients. The levels of the antibody increased with the progression of the disease and declined in treated patients. The results strongly suggest that tests measuring serum antibody against EBV DNA polymerase activity can be used for early diagnosis and prognosis of NPC.
π SIMILAR VOLUMES
The Epstein-Barr virus (EBV) is a ubiquitous Herpes virus which causes infectious mononucleosis and is associated with such different neoplasms as Burkitt's lymphoma and nasopharyngeal carcinoma. EBV latently infects its target cells; nevertheless, evidence of viral replication in NPC tumours has be
## RESULTS. In specimens from 107 patients with NPC, EBV was detected by PCR in 2 Department of Pathology, the Johns Hopkins 97 cases (90.7%) and by EBER in situ hybridization in 105 cases (98.1%). In speci-
The Epstein-Barr virus (EBV) open reading frame BHRF1, a homologue of the oncogene bcl-2, was cloned from a patient with nasopharyngeal carcinoma (NPC) and overexpressed in Escherichia coli. The resulting recombinant BHRF1 fusion protein, with an apparent molecular weight of 35 KD, was used as antig
## Abstract Biopsy specimens from Alaskan Native patients with nasopharyngeal carcinoma (NPC) and from other patients seen on the otolaryngology service were tested for EpsteinβBarr virusβspecific DNA and nuclear antigen (EBNA). Serum samples from both groups were tested for various EBVβrelated ant